In an aggressive push to wipe out substandard and unlicensed medicines, the Food and Drug Administration (FDA), Maharashtra, has dramatically intensified enforcement across pharmaceutical manufacturing and retail operations. Official data reveals an unprecedented ramp-up in vigilance between June and September 2026 compared to the preceding two months.

More checks

Average monthly inspections rose 4.6 times, leaping from 234 checks per month in April-May (467 total) to 1064 between June and September 4256 total. Overall inspection target achievement increased from 29 per cent to 131 per cent. Retail inspections reached 141 per cent of the target, while manufacturing checks reached 106 per cent.